> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Resume User Fee Talks: Disease Interests
- URL: https://www.fdaweb.com/resume-user-fee-talks-disease-interests/
- Published: 2022-08-04T12:00:00.000Z
- Updated: 2026-09-14T17:54:44.000Z
- Author: David McFarland
- Tags: Drugs, Devices, #legacy-id-D5152448

Some 99 organizations that represent patients with rare diseases and other acute or chronic health conditions are urging congressional leadership to “resume negotiations to develop a comprehensive FDA user fee package.” In an 8/1 [letter](https://cqrcengage.com/mda/file/jHF0kvaFt3j/08.1.2022%20Patient%20User%20Fee%20Authorization%20Letter.pdf?ref=fdaweb.com), the organizations say they are “deeply concerned about the impact that a delay in passage of this legislation will have on FDA’s ability to conduct the timely reviews of critical products that our patients need….” They say other important policies must be considered as part of the user fee reauthorization process and they urge the House and Senate to “quickly develop robust, consensus legislation.”

Citing policy provisions that appear in one chamber’s version of a user fee bill but not the other chamber’s, the groups say “Congress should capitalize on the user fee reauthorization process to consider and enact the additional policies that would have little chance of passage as standalone bills, just as it has every five years since 1992\. To pass a ‘clean’ user fee package would be to walk away from an opportunity to make critical improvements in our nation’s system for overseeing medical products. We urge you to immediately work together to blend your respective bills and continue Congress’ longstanding tradition of passing strong, bipartisan FDA legislation to the benefit of all Americans.”